HOW IT WORKS

We sit above the intelligence layer —
and inside the organisational one.

Frontier models are good at science. We make them good at running a biotech. Tribal·Bio is a synthetic workforce — agentic swarm teams tuned to your asset, indication, and stage — that reason over regulatory guidance, draft documents, reach out to agencies and CDMOs, run simulations, and close the organisational loops that real drug development actually requires.

THE STACK

Two layers. We are the top one.

TRIBAL LAYER

Organisational layer

Synthetic employees with the judgment and institutional memory of a pharma org. They run workflows end-to-end: regulatory strategy, CMC, clinical, commercial. They email agencies, negotiate with CDMOs, model markets, and hand you decisions — not prompts.

sits above

FOUNDATION

Intelligence layer

Frontier LLMs, scientific tools, public databases — PubMed, ClinicalTrials.gov, ICD-10, bioRxiv. Good at reasoning and retrieval. Generic. We use them, we don't replace them.

WHAT YOUR TEAM DOES

A synthetic workforce with centuries of experience.

Regulatory reasoning

We collate and internalise how regulatory agencies — FDA, EMA, MHRA, PMDA — actually think. Our agents know which documents belong at which stage, which guidance applies, which comparators regulators expect, and where pre-IND meetings historically unlock or stall programs.

Document drafting

Briefing documents, pre-IND packages, INDs, Target Product Profiles, SAPs, IBs, agency meeting requests. Drafted in the sponsor's voice, traceable, and reviewed across the synthetic team before they land in your inbox.

Asset advisory

We give you real opinions — go / no-go reads on assets, risk maps, competitor intelligence, reformulation paths, delivery platforms, orphan vs. broader indication framing — informed by the full sponsor corpus, not the open web alone.

Simulations

Agentic swarm teams simulate tox outcomes, PK/PD profiles, trial enrollments, payer negotiations, and launch scenarios before you commit capital. You see the model; you see the variance; you see the levers.

Real-world outreach

Your synthetic employees don't stop at the console. They email the FDA, schedule pre-IND meetings, request CDMO quotes, negotiate contract language, draft payer dossiers, and coordinate with KOLs — under your authorisation.

Commercialisation

Market sizing, launch modeling, payer strategy, MSL narratives, partnership targeting. The same synthetic team that drafted your IND carries the program through to launch — with institutional memory that never leaves.

STAGE-AWARE

The team reshapes for your stage.

You don't get one generic copilot. You get a team assembled for your asset, indication, and moment in development.

STAGE 01

Discovery & evaluation

Literature sweep, target validation, IP landscape, competitor trials, preliminary TPP.

→

STAGE 02

Preclinical

Tox strategy, species selection, CDMO shortlisting, manufacturing feasibility, IND-enabling plan.

→

STAGE 03

Regulatory & clinical

Pre-IND briefing, IND authoring, Phase I design, site selection, agency correspondence.

→

STAGE 04

Commercial & launch

TAM + payer modeling, MSL strategy, launch readiness, partnership scouting, lifecycle planning.

THE VISION

The standard operating system
for pharmaceutical teams.

Drug development today is logistics disguised as science. Emails, chase-ups, scheduling, document hand-offs, agency back-and-forth, CDMO quotes, commercial modeling — most of a team's time is spent coordinating, not thinking. Tribal·Bio absorbs that logistics layer. Over time, the platform becomes the place biotechs are built, run, and grown — the default operating system for the next generation of pharma.

Open the console → Back to overview

We sit above the intelligence layer — and inside the organisational one.